Elos Medtech appoints Jan Wahlström as new President and CEO as of 1 July 2016

As previously announced, President Johannes Lind-Widestam has decided to step down effective 30 June 2016. Johannes Lind-Widestam will be succeeded by Jan Wahlström, who will take up his position on 1 July 2016. Jan joins Elos Medtech from his role as President of Larodan AB. Larodan develops, manufactures and markets high-quality lipids for chemical research in the international market. Previous positions held include President of Biolin Scientific and senior positions at several medical technology companies.

Stig-Arne Blom, Chairman of the Board of Elos Medtech says: “We are extremely pleased to have recruited Jan Wahlström to our team as our new CEO. Jan’s personality and professional experience make him highly suitable to take over the leadership of Elos Medtech. He has been tasked with, on a global basis, continuing to develop our operations and strengthening our positions in selected market segments.

“In parallel, I would like to thank Johannes Lind-Widestam for his achievements during his period as President. Under the leadership of Johannes, the Group’s medical technology focus has been further strengthened through, inter alia, the acquisition of Onyx Medical but also through investments in our own products.”

Jan Wahlström says: “Elos Medtech is a high-quality company well-positioned in the medical technology sector. It is extremely inspiring to be given this opportunity to take over leadership of the Group.”

Elos Medtech is one of Europe's leading development and production partners for medical technology products and components, such as dental and orthopaedic implants and instruments. The operations are conducted at facilities in Sweden, Denmark, China and the US. Customers are internationally active medical technology companies.

Elos Medtech Group’s turnover is approximately MSEK 550 and has about 520 employees. The Group has been traded on NASDAQ Stockholm AB since 1989. The Elos Medtech B share is classified as a Health Care company on the Small Cap list.


Lidköping, 1 June 2016

Elos Medtech AB (publ)


For further information, please contact:
Stig-Arne Blom, Chairman of the Board, +46 705 25 16 15, e-mail stigarne@blom.pp.se


For further information, visit www.elosmedtech.com

The information in this press release is such that Elos Medtech AB is obligated to publish in accordance with the Securities Market Act and/or the Financial Instruments Trading Act.

The information was issued for publication on 1 June 2016, at 8:00 a.m. (CET).

Tags:

About Us

Elos Medtech is one of Europe's leading development and production partners for medical technology products and components, such as dental and orthopaedic implants and instruments. The operations are conducted at facilities in Sweden, Denmark, China and USA. Customers are mainly internationally active medical technology companies in the market segments Dental Implant Systems, Diagnostics, Medical Devices and Trauma & Spine. The Group’s net sale is approximately SEK 560 M and has about 520 employees. The Group is since 1989 traded on NASDAQ OMX Stockholm AB. The shares are classified as a Health Care company on the Small Cap list.

Subscribe

Documents & Links